Sign In
Buy VERA
$31.58
-1.31 (-3.98%)
At Close: Aug 10, 2026
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
04:01pm, Monday, 08'th Dec 2025
BRISBANE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformat
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 05'th Dec 2025
BRISBANE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on December 2, 2025, the Compensation Committee of the Board of Directors of Vera Thera
Vera Therapeutics, Inc. (VERA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
06:23pm, Wednesday, 03'rd Dec 2025
Vera Therapeutics, Inc. (VERA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
American Century Companies Inc. Raises Position in Vera Therapeutics, Inc. $VERA
03:18am, Wednesday, 03'rd Dec 2025
American Century Companies Inc. increased its stake in Vera Therapeutics, Inc. (NASDAQ: VERA) by 89.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The i
Why Vera Therapeutics Stock Rocked the Market on Tuesday
07:42pm, Tuesday, 02'nd Dec 2025
The biotech received a significant boost from a new analyst note. The prognosticator authoring it reiterated his strong buy recommendation on the stock.
Why Vera Therapeutics Stock Crushed it Today
07:45pm, Wednesday, 26'th Nov 2025
An analyst expressed his very bullish view on the biotech in a new research note. He reiterated his equivalent of a buy recommendation, and his lofty price target.
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors
04:05pm, Wednesday, 26'th Nov 2025
BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme
Vera Therapeutics to Participate at Upcoming Investor Conferences
07:25am, Monday, 24'th Nov 2025
BRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme
Yale University's Strategic Investment in Vera Therapeutics Inc: A 32.26% Portfolio Stake
09:01am, Friday, 14'th Nov 2025
Exploring Yale's Investment Moves in the Third Quarter of 2025 Yale University (Trades, Portfolio) recently submitted its 13F filing for the third quarter of 2
Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
07:29am, Monday, 10'th Nov 2025
BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme
Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN ORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% r
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 07'th Nov 2025
BRISBANE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 4, 2025, the Compensation Committee of the Board of Directors of Vera Thera
Vera Therapeutics, Inc. (VERA) Discusses Interim Results of ORIGIN Phase 3 Trial of Atacicept for IgA Nephropathy Transcript
11:26pm, Thursday, 06'th Nov 2025
Vera Therapeutics, Inc. ( VERA ) Discusses Interim Results of ORIGIN Phase 3 Trial of Atacicept for IgA Nephropathy November 6, 2025 4:30 PM EST Company Participants Marshall Fordyce - Founder, Presid
BRISBANE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced data from the ORIGIN Phase 3 trial of atacicept in IgA nephropathy (IgAN) were presented as a
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
07:29am, Wednesday, 05'th Nov 2025
ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology
